跳至主要内容
临床试验/ACTRN12615000362594
ACTRN12615000362594终止4 期

Comparing risk of relapse in Graves' disease patients treated with fixed-time carbimazole vs. treatment guided by TRAb titre

Royal Brisbane & Women's Hospital Foundation0 个研究点目标入组 24 人开始时间: 2015年4月21日最近更新:
适应症

试验速览

阶段
4 期
状态
终止
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • First presentation of Graves’ disease as defined as hyperthyroidism (free T4 and/or free T3 above the upper limit of normal with TSH suppressed below the lower limit of normal - <0.3mU/L) associated with elevated TSH-receptor antibody (TRAb) (>1.5 U/mL)

排除标准

  • - Greater than three months since first diagnosis of Graves’ disease
  • - Age less than 18 years
  • - Current or planned pregnancy within the next three years
  • - Current breastfeeding
  • - Clinical or imaging suspicion of thyroid cancer
  • - TRAb negative status at time of diagnosis,
  • - Potential participant or treating physician desire primary treatment with surgery or radioiodine therapy
  • - Concomitant treatment with lithium, corticosteroids, amiodarone, Lugol’s iodine

研究者

相似试验